Advanced Medical Optics — Merger or Acquisition (November 2004)
40 slides from Advanced Medical Optics's merger presentation, Nov 30, 2004

Slide 1: Advanced Medical Optics
ADVANCED MEDICAL OPTICS Nov/Dec 2004 Filed by Advanced Medical Optics, Inc., Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Advanced Medical Optics, Inc. Commission File No. 001-31257 This fili

Slide 2: Forward Looking Statements
Forward Looking Statements Our statements in this presentation that discuss projected demographics and markets, statements regarding the expected timing and benefits of the VISX transaction, statements under the heading "2004-2005 Launch Highlights," and all slides under the heading "Financial and O

Slide 3: Advanced Medical Optics, Inc.
Advanced Medical Optics, Inc. Global ophthalmic medical device company Leading positions in large markets with robust growth drivers Technology leader with heritage of innovation and high brand awareness Demonstrated pattern of growth in revenue, cash flow and EPS since June 2002 spin-off Blend of g

Slide 4: Diversified Global Revenue
Cataract 59% Eye Care 39% Americas 28% Europe 37% Japan 26% 9% Diversified Global Revenue Pro forma Revenue Mix Asia Pacific Refractive 2% LTM period is defined as the last twelve months ended September 24, 2004. Pro Forma for the Pfizer Surgical Business, see "Historical Financial Statements" under

Slide 5: Global Coverage
Eye Care 49% Americas 30% Global Coverage Direct Sales In 20 Countries, Presence In 60+ Leading Market Share Positions State-of-the-Art Manufacturing on 3 Continents

Slide 6: AMO to Acquire VISX
AMO to Acquire VISX Creates world's leading refractive surgical business Establishes $1 billion enterprise with increased earnings power and cash flow potential Provides surgeons and patients a comprehensive portfolio of technologies and brands Provides operating efficiencies by better utilizing inf

Slide 7: Transaction Highlights
Transaction Highlights $26.52 per VISX share or $1.27 billion (1) 87% AMO stock and 13% cash; tax-free exchange 0.552 shares of AMO and $3.50 cash for each VISX share Pro forma ownership of 58.5% AMO/41.5% VISX Expected to be neutral to 2005 EPS; accretive to 2006 EPS Enhances revenue growth, expand

Slide 8: AMO and VISX: Compelling Strategic, Technological and Cultural Fit
VISX Brings. . . Global leader in laser vision correction Ongoing technological innovation Focused, experienced management team Unsurpassed customer support AMO Brings ... Global leader Innovator with well-recognized brands Worldwide distribution Experienced management team with record of discipline

Slide 9: Vision Care Life Cycle
GLAUCOMA Contact Lenses REFRACTIVE CATARACT Eye Lubricants Microkeratomes Phakic IOLs Accommodating IOLs Multifocal IOLs Monofocal IOLs Phaco & Lens Extraction EYE CARE Viscoelastics Glaucoma Shunts Contact Lens Care Solutions Excimer Lasers Vision Care Life Cycle Improving Practitioner Productivity

Slide 10: Cataract & Glaucoma: Worldwide Aging Fuels Market
CATARACT & GLAUCOMA Worldwide Aging Fuels Market Cataract Is Leading Cause of Blindness, Affecting Half of People Over 60 Glaucoma Is Chronic Disease Percentage Aged 65+ Cataract Glaucoma Source: US Census Bureau, 2000. Photos: National Eye Institute

Slide 11: Refractive: Baby Boomers Fuel Surgical Market
REFRACTIVE Baby Boomers Fuel Refractive Surgical Market Growing Segment Looking for Refractive Options Projected Change in Population Growth 2000-2010 45-54 55-64 Source: US Census Bureau, 2000. Photos: National Eye Institute

Slide 12: Eye Care: Teens and Young Adults Are Primary Contact Lens Wearers
EYE CARE Teens and Young Adults Are Primary Contact Lens Wearers Echo Boomers Make Up Majority of New Fits Projected Population Totals of People Aged 14-24 Source: US Census Bureau, 2000

Slide 13: Ophthalmic Surgical
Ophthalmic Surgical

Slide 14: Pro Forma Surgical Revenue Mix
Phaco 15% IOL 51% Americas 35% Japan 17% Europe 40% 8% Visco 27% Pro forma Surgical Revenue Mix Refractive 3% Product Geography Other 4% Asia Pacific LTM period is defined as the last twelve months ended September 24, 2004. Pro Forma for the Pfizer Surgical Business, see "Historical Financial Statem

Slide 15: AMO Cataract Products
Viscoelastics Phaco Systems Inserters Creates space and protects ocular surfaces during surgery Addition of Healon ® family creates complete offering AMO Cataract Products Replaces human lens during cataract surgery Dual platform (silicone and acrylic) Dual optical design (mono and multifocal) Ultra

Slide 16: Technological Opportunity with Tecnis
Technological Opportunity with Tecnis ® First IOL with FDA labeling for improved functional vision Reduces postoperative spherical aberrations compared to lenses with spherical optics Improved night-driving simulator performance Patients asked to detect/identify targets under rural night and nightti

Slide 17: 52% of U.S. Population Has Some Form of Refractive Error
Myopia Hyperopia Source: U.S. Census Bureau, American Academy of Ophthalmology. Figures represent projections for 2005. ~ 68.75MM People ~74.25MM People 52% of U.S. Population Has Some Form of Refractive Error

Slide 18: U.S. Population Amplitude of Accommodation
U.S. Population Amplitude of Accommodation U.S. Population with Presbyopia Eye's ability to accommodate - change focus from far to near - continues to decline with age Few surgical options exist today; vast majority rely on bifocals or readers Opportunity to address huge unmet need Age Age in 2004 A

Slide 19: Refractive Opportunities
Pre-Presbyopia Presbyopia Presbyopia/ Cataract High Myopia >-6D Low/Moderate Myopia <-6D Low/Moderate Hyperopia <+6D Moderate/High Hyperopia >+6D Laser Phakic CK Multifocal Accommodating Multifocal Accommodating Multifocal Accommodating Multifocal Accommodating Multifocal Multifocal phakic Laser Mul

Slide 20: Refractive Multifocal IOLs
Tecnis Multifocal Array / ReZoom Refractive Multifocal IOLs Diffractive technology Provides near and far vision under all light conditions Approved for correction of presbyopia in Europe Refractive technology Cataract claim in US with NTIOL status Approved for correction of presbyopia in Europe AC P

Slide 21: Verisyse Refractive Phakic IOLs
Verisyse TM Refractive Phakic IOLs Anterior chamber, iris-fixated IOL for correction of myopia Natural crystalline lens remains intact FDA approved; first lens of its kind in US 15-year history in Europe Safely inserted in more than 150,000 eyes

Slide 22: VISX: Ongoing Technology Leadership
VISX: Ongoing Technology Leadership CustomVue Comprehensive measurement and correction Potentially better than contacts or glasses Fourier Wavefront Upgrade Unprecedented resolution for individualized CustomVue treatment Iris Registration First fully automated technology to correct for eye rotation

Slide 23: Microkeratomes
Microkeratomes Refractive LASIK Products Precision cutting device creates corneal flap in LASIK surgery Designed and developed for safety, simplicity, reliability #1 Preferred Mechanical Microkeratome (1) Faster visual recovery than femtosecond laser (2) Less pain than femtosecond laser (3) Less dry

Slide 24: Eye Care
Eye Care

Slide 25: Eye Care Revenue Mix
Multipurpose 46% Hydrogen Peroxide 32% Americas 19% Europe 32% Japan 39% Other 22% 10% Eye Care Revenue Mix Product Geography Asia Pacific LTM period is defined as the last twelve months ended September 24, 2004.

Slide 26: Eye Care Products
Multipurpose Solutions Hydrogen Peroxide Lubricants Contact Lenses Eye Care Products Offering superior comfort Convenient one-bottle system Artificial tear ingredients relieve dryness and discomfort Multi-bottle system Significant market penetration Preservative-free Built-in comfort agents Lubricat

Slide 27: Contact Lens Growth Fuels Eye Care
Market Drivers Contact Lens Growth Fuels Eye Care Contact lens market expected to grow 8-10% annually Growing teen/young adult segment Environmental factors increasing incidence of myopia Significant momentum from specialty, value- added lenses Torics for astigmatism Bifocals and multifocals for pre

Slide 28: Corporate R&D / Corporate Development
R&D / Corporate Development

Slide 29: Commitment to Innovation
AMO FIRSTS 2001-2003: 26% Growth in R&D Investment Commitment to Innovation Foldable IOL Multifocal IOL in U.S. "Cold" Phaco Capability Peroxide Disinfection System Multipurpose Solution to Address Comfort and Dryness Percentages in bar graph represent R&D spend as a % of sales 2000 2001 Eye Care Su

Slide 30: Hallmark of Continuous Innovation
Hydrocare® COMPLETE® Comfort Plus COMPLETE ® COMPLETE® Pro-Tec COMPLETE® Pro-Tec No-Rub COMPLETE® Moisture Plus TM UNFOLDER ® Insertion Systems Phacoflex ® Array ® Sensar ® OptiEdge TM Sensar ® Array ® II SI30 SI40 SI55 OptiEdge TM Clariflex ® Hallmark of Continuous Innovation Surgical - IOL Technol

Slide 31: 2004-2005 Launch Highlights
Launched Launched Launched Launched Launched Launched Launched Eye Care Refractive Cataract 2004-2005 Launch Highlights 2005 Tecnis ® Acrylic 2005 Epi-Lasik for Amadeus II (US/E/AP) 2004 Tecnis ® Multifocal 2004 ReZoom TM (E/US) (1) 2005 COMPLETE 10-Minutes (J) 2004/2005 Amadeus II (US/E) 2004 blink

Slide 32: Business Development Builds Portfolio, Expands Markets
Expand portfolio of accommodating IOLs to address presbyopia Research & Evaluation Licensing Agreement Complete cataract franchise, expand refractive technologies Acquisition Licensing Strategic Partnership & Distribution Strategic Partnership & Distribution Expand portfolio of refractive IOLs and C

Slide 33: Financial and Operational Performance
Financial and Operational Performance

Slide 34: Returned AMO to Revenue Growth
Returned AMO to Revenue Growth * = Constant currency growth (in millions) $570.6 $543.1 $538.1 $601.5 $684.4

Slide 35: Continued EBITDA Growth
Continued EBITDA Growth CAGR 13.2% (in millions) $58.6 $63.0 $72.6 $75.1 $93.4 Pro forma operating income, see "Historical Financial Statements" under Investor/Media at www.amo- inc.com for GAAP

Slide 36: Pro Forma Net Earnings Growth
Pro Forma Net Earnings Growth CAGR 38.6% Pro forma net earnings and EPS, see "Historical Financial Statements" under Investors/Media at www.amo-inc.com for GAAP (in millions)

Slide 37: Balance Sheet Highlights
9/24/04 12/31/03 Balance Sheet Highlights $193.6 $93.2 Stockholders' Equity $568.4 $233.3 Long-term Debt (Principal) $90.7 $42.0 Inventories $180.9 $70.0 Trade receivables, net $34.1 $46.1 Cash and equivalents (in millions)

Slide 38: 2004-2006 Guidance
2004 -2006 Guidance (in millions) 2005 and 2006 guidance pro forma for VISX acquisition assuming close in Q1 2005; for reconciliation to GAAP and rationale for use of pro forma, see Investors/Media at www.amo-inc.com

Slide 39: AMO Positioned for Value Creation
AMO Positioned for Value Creation Solid positions in large markets with favorable growth drivers AMO/VISX combination creates global leader in high-growth refractive segment Technology leader with rich pipeline through blend of internal R&D and corporate development Scalable global infrastructure fo

Slide 40: Additional Information
Additional Information AMO and VISX intend to file with the SEC a Registration Statement on Form S-4, which will include a joint proxy statement/prospectus of VISX and AMO and other relevant materials in connection with the proposed transaction. The joint proxy statement/prospectus will be mailed to
Source: SEC EDGAR · 425 filed Nov 30, 2004
